Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurodegeneration, Fibrosis, and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CAPN2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Active Enzyme | CAPN2/CAPNS1 Heterodimer Complex. High purity (>95%), Sequence Verified, HEK293 Expressed. Includes catalytically competent large subunit with regulatory small subunit. | View CAPN2 Products |
| Catalytic Dead Control | CAPN2 C105S Mutant Protein. Active site cysteine to serine mutation for mechanism studies. Endotoxin Controlled. | View CAPN2 Products |
| Antigen / Mutant Recombinant | CAPN2 Mutant Recombinant Protein (Catalytic domain). High purity (>95%), Endotoxin <1EU/ug, Sequence Verified. | View CAPN2 Products |
| Gene Delivery | CAPN2 Promise-ORF / Lentivirus. Full-length ORF for stable cell line construction. | View CAPN2 Products |
| Benchmark Antibody | Anti-CAPN2 Recombinant Monoclonal Antibody. High-affinity reference for Western Blot and IP. | View CAPN2 Products |
| Validator | CAPN2 siRNA Set. Sequence-verified siRNA panel for specific knockdown and target validation. | View CAPN2 Products |
| Related Target A | CAPN1 (Calpain-1 Large Subunit). Essential counter-screening target (μ-calpain) to verify CAPN2 (m-calpain) isoform selectivity. | View CAPN1 Products |
| Related Target B | CAPNS1 (Calpain Small Subunit 1). Common regulatory subunit essential for structural stability and full catalytic activation. | View CAPNS1 Products |
| Related Target C | CAST (Calpastatin). Endogenous specific inhibitor of calpains; critical control for inhibition assays. | View CAST Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (CAPN2 vs CAPN1) | Human CAPN2 and CAPN1 recombinant proteins available separately with >95% purity, sequence-verified for distinct epitope mapping. |
| Heterodimer Reconstitution with CAPNS1 | CAPN2 large subunit + CAPNS1 small subunit co-expression available; endotoxin-controlled for biophysical assays. |
| Intracellular Target Engagement & Permeability | Cell-based assays supported by CAPN2 Lentivirus stable cell lines; CAST co-expression controls included. |
| False Positives / Assay Specificity | Validated CAPN2 siRNA included for target-specificity confirmation in cellular phenotypic screens. |
Live CAPN2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CAPN2 (Calpain-2) therapeutics is intensifying as researchers pivot from early-generation broad-spectrum cysteine protease inhibitors toward highly selective, domain-specific small molecules and allosteric modulators. Historically, clinical translation was hindered by poor isoform selectivity between CAPN1 (μ-calpain) and CAPN2 (m-calpain), and off-target reactivity with lysosomal cathepsins. Today, structural biology and rational drug design have unlocked novel allosteric binding pockets unique to CAPN2. Next-wave modalities include isoform-selective small molecule inhibitors, peptide/protein inhibitors derived from Calpastatin (CAST), and targeted protein degraders (PROTACs). By selectively inhibiting pathological CAPN2 hyperactivation during sustained calcium influx—without disrupting CAPN1-dependent baseline physiology—these approaches open therapeutic avenues in traumatic brain injury (TBI), cardiac ischemia-reperfusion injury, idiopathic pulmonary fibrosis (IPF), fibrotic diseases, and invasive solid tumors.
Key CAPN2 mutations (dbSNP: rs25655, rs2230083, rs9804140) are under study for potential impact on inhibitor binding and disease susceptibility, though no clinically actionable variants have been identified to date.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Isoform-Selective Inhibitors) | AbbVie, Blade Therapeutics, AmeriDx | Fibrosis (IPF), Neurodegeneration (TBI, Alzheimer's) | FRET Enzymatic Selectivity Panel (Need high-purity CAPN2 and CAPN1 heterodimers) |
| Allosteric Modulators | Academic Consortia, Emerging Biotechs | Cardiac Ischemia-Reperfusion, Glaucoma | Calcium-Shift & Conformational Assays (Need HEK293-expressed native heterodimers) |
| Peptide/Protein Inhibitors (CAST-based) | Preclinical platform developers | Traumatic Brain Injury, Cataracts | Heterodimer Disruption (Need CAPN2-CAPNS1 complex reconstitution) |
| PROTAC / Targeted Degradation | Preclinical Discovery Programs | Metastatic Solid Tumors (Breast, Colorectal) | Ternary Complex & Degradation Verification (Need sequence-verified antigens & siRNA controls) |